Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint
Katarzyna Magiera‐Mularz, Łukasz Skalniak, Krzysztof M. Zak, et al.
Angewandte Chemie International Edition (2017) Vol. 56, Iss. 44, pp. 13732-13735
Open Access | Times Cited: 149

Showing 1-25 of 149 citing articles:

Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges
Alexander A. Vinogradov, Yizhen Yin, Hiroaki Suga
Journal of the American Chemical Society (2019) Vol. 141, Iss. 10, pp. 4167-4181
Closed Access | Times Cited: 657
The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
Weiting Qin, Li-Peng Hu, Xueli Zhang, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 327
Role of tumor microenvironment in cancer progression and therapeutic strategy
Qingjing Wang, Xueting Shao, Yuxuan Zhang, et al.
Cancer Medicine (2023) Vol. 12, Iss. 10, pp. 11149-11165
Open Access | Times Cited: 165
Immunomodulators targeting the PD‐1/PD‐L1 protein‐protein interaction: From antibodies to small molecules
Jeffrey Yang, Longqin Hu
Medicinal Research Reviews (2018) Vol. 39, Iss. 1, pp. 265-301
Open Access | Times Cited: 164
Self-Delivery Photo-Immune Stimulators for Photodynamic Sensitized Tumor Immunotherapy
Linping Zhao, Rongrong Zheng, Jiaqi Huang, et al.
ACS Nano (2020) Vol. 14, Iss. 12, pp. 17100-17113
Closed Access | Times Cited: 141
<p>Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy</p>
Leilei Ai, Jian Chen, Hao Yan, et al.
Drug Design Development and Therapy (2020) Vol. Volume 14, pp. 3625-3649
Open Access | Times Cited: 139
Peptide-based supramolecular hydrogels for local drug delivery
Zhenghao Zhang, Sifan Ai, Zhimou Yang, et al.
Advanced Drug Delivery Reviews (2021) Vol. 174, pp. 482-503
Closed Access | Times Cited: 136
Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions
Xuefei Wang, Duan Ni, Yaqin Liu, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 109
Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation
Tianyu Wang, Shi Cai, Yao Cheng, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 5, pp. 3879-3893
Closed Access | Times Cited: 88
Peptides as multifunctional players in cancer therapy
Sri Murugan Poongkavithai Vadevoo, Smriti Gurung, Hyun‐Su Lee, et al.
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 6, pp. 1099-1109
Open Access | Times Cited: 84
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
Holly K. Koblish, Liangxing Wu, Liang‐Chuan S. Wang, et al.
Cancer Discovery (2022) Vol. 12, Iss. 6, pp. 1482-1499
Open Access | Times Cited: 81
Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
Sadique A. Javed, Asim Najmi, Waquar Ahsan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 27
Macrocycles and macrocyclization in anticancer drug discovery: Important pieces of the puzzle
Chao Zhang, Fenfen Liu, You‐Ming Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116234-116234
Closed Access | Times Cited: 18
Development of the Inhibitors That Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles
Katarzyna Guzik, Marcin D. Tomala, Damian Muszak, et al.
Molecules (2019) Vol. 24, Iss. 11, pp. 2071-2071
Open Access | Times Cited: 130
CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?
Bogdan Musielak, Justyna Kocik, Łukasz Skalniak, et al.
Molecules (2019) Vol. 24, Iss. 15, pp. 2804-2804
Open Access | Times Cited: 128
Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules
Xin Lin, Xiang Lu, Guoshun Luo, et al.
European Journal of Medicinal Chemistry (2019) Vol. 186, pp. 111876-111876
Closed Access | Times Cited: 126
Immune Checkpoint PD‐1/PD‐L1: Is There Life Beyond Antibodies?
Markella Konstantinidou, Tryfon Zarganes‐Tzitzikas, Katarzyna Magiera‐Mularz, et al.
Angewandte Chemie International Edition (2017) Vol. 57, Iss. 18, pp. 4840-4848
Open Access | Times Cited: 125
A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018)
Shabnam Shaabani, Harmen P.S. Huizinga, Roberto Butera, et al.
Expert Opinion on Therapeutic Patents (2018) Vol. 28, Iss. 9, pp. 665-678
Open Access | Times Cited: 124
Peptide-based PET quantifies target engagement of PD-L1 therapeutics
Dhiraj Kumar, Ala Lisok, Elyes Dahmane, et al.
Journal of Clinical Investigation (2018) Vol. 129, Iss. 2, pp. 616-630
Open Access | Times Cited: 119
Comprehensive in vitro characterization of PD-L1 small molecule inhibitors
Aravindhan Ganesan, Marawan Ahmed, Isobel Okoye, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 112
Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
Hao Liu, Zhen Zhao, Li Zhang, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 103
Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway
Tianyu Wang, Xiaoxing Wu, Changying Guo, et al.
Journal of Medicinal Chemistry (2018) Vol. 62, Iss. 4, pp. 1715-1730
Closed Access | Times Cited: 102
Crystal Structures of Protein-Bound Cyclic Peptides
Alpeshkumar K. Malde, Timothy A. Hill, Abishek Iyer, et al.
Chemical Reviews (2019) Vol. 119, Iss. 17, pp. 9861-9914
Closed Access | Times Cited: 87
Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways
Pottayil G. Sasikumar, Murali Ramachandra
BioDrugs (2018) Vol. 32, Iss. 5, pp. 481-497
Open Access | Times Cited: 86
Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
Subhadwip Basu, Jeffrey Yang, Bin Xu, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 15, pp. 7250-7263
Closed Access | Times Cited: 84
Page 1 - Next Page

Scroll to top